These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20367793)

  • 1. Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48.
    Kim JH; Yim HJ; Jung ES; Jung YK; Kim JH; Seo YS; Yeon JE; Lee HS; Um SH; Byun KS
    J Viral Hepat; 2011 Apr; 18(4):287-93. PubMed ID: 20367793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment efficacy of clevudine, entecavir and lamivudine in treatment-naive patients with HBeAg-positive chronic hepatitis B].
    Bae SH; Baek YH; Lee SW; Han SY
    Korean J Gastroenterol; 2010 Dec; 56(6):365-72. PubMed ID: 21173560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labelled prospective study.
    Ko SY; Kwon SY; Choe WH; Kim BK; Kim KH; Lee CH
    Antivir Ther; 2009; 14(4):585-90. PubMed ID: 19578244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B.
    Kim SB; Song IH; Kim YM; Noh R; Kang HY; Lee HIe; Yang HY; Kim AN; Chae HB; Lee SH; Kim HS; Lee TH; Kang YW; Lee ES; Kim SH; Lee BS; Lee HY
    World J Gastroenterol; 2012 Dec; 18(47):6943-50. PubMed ID: 23322992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy.
    Lee KS; Byun KS; Chung YH; Paik SW; Han JY; Yoo K; Yoo HW; Yoo BC; Lee HS
    Intervirology; 2007; 50(4):296-302. PubMed ID: 17622789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy.
    Jang JH; Kim JW; Jeong SH; Myung HJ; Kim HS; Park YS; Lee SH; Hwang JH; Kim N; Lee DH
    J Viral Hepat; 2011 Feb; 18(2):84-90. PubMed ID: 20196804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.
    Marcellin P; Mommeja-Marin H; Sacks SL; Lau GK; Sereni D; Bronowicki JP; Conway B; Trepo C; Blum MR; Yoo BC; Mondou E; Sorbel J; Snow A; Rousseau F; Lee HS
    Hepatology; 2004 Jul; 40(1):140-8. PubMed ID: 15239097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B.
    Kim HJ; Park DI; Park JH; Cho YK; Sohn CI; Jeon WK; Kim BI
    Liver Int; 2010 Jul; 30(6):834-40. PubMed ID: 20408946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.
    Yoo BC; Kim JH; Kim TH; Koh KC; Um SH; Kim YS; Lee KS; Han BH; Chon CY; Han JY; Ryu SH; Kim HC; Byun KS; Hwang SG; Kim BI; Cho M; Yoo K; Lee HJ; Hwang JS; Kim YS; Lee YS; Choi SK; Lee YJ; Yang JM; Park JW; Lee MS; Kim DG; Chung YH; Cho SH; Choi JY; Kweon YO; Lee HY; Jeong SH; Yoo HW; Lee HS
    Hepatology; 2007 Oct; 46(4):1041-8. PubMed ID: 17647293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B virus infection: two-year follow-up data.
    Yoon EL; Yim HJ; Lee HJ; Lee YS; Kim JH; Jung ES; Kim JH; Seo YS; Yeon JE; Lee HS; Um SH; Byun KS
    J Clin Gastroenterol; 2011; 45(10):893-9. PubMed ID: 21617542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study.
    Lau GK; Leung N
    Korean J Hepatol; 2010 Sep; 16(3):315-20. PubMed ID: 20924215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes of clevudine versus lamivudine at week 48 in naïve patients with HBeAg positive chronic hepatitis B.
    Kim IH; Lee S; Kim SH; Kim SW; Lee SO; Lee ST; Kim DG; Choi CS; Kim HC
    J Korean Med Sci; 2010 May; 25(5):738-45. PubMed ID: 20436711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of 48-week clevudine therapy for chronic hepatitis B].
    Kim MH; Kim KA; Lee JS; Lee HW; Kim HJ; Yun SG; Kim NH; Bae WK; Moon YS
    Korean J Hepatol; 2009 Sep; 15(3):331-7. PubMed ID: 19783882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases].
    Lee HJ; Eun JR; Lee CH; Hwang JS; Suh JI; Kim BS; Jang BK
    Korean J Hepatol; 2009 Jun; 15(2):179-92. PubMed ID: 19581770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of initial treatment with clevudine in naive patients with chronic hepatitis B.
    Yang HW; Lee BS; Lee TH; Lee HY; Nam KW; Kang YW; Chae HB; Kim SH; Kim SB; Lee HIe; Kim AN; Song IH; Lee SH; Kim HS
    Korean J Intern Med; 2010 Dec; 25(4):372-6. PubMed ID: 21179274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B.
    Yoo BC; Kim JH; Chung YH; Lee KS; Paik SW; Ryu SH; Han BH; Han JY; Byun KS; Cho M; Lee HJ; Kim TH; Cho SH; Park JW; Um SH; Hwang SG; Kim YS; Lee YJ; Chon CY; Kim BI; Lee YS; Yang JM; Kim HC; Hwang JS; Choi SK; Kweon YO; Jeong SH; Lee MS; Choi JY; Kim DG; Kim YS; Lee HY; Yoo K; Yoo HW; Lee HS
    Hepatology; 2007 May; 45(5):1172-8. PubMed ID: 17464992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clevudine demonstrates potent antiviral activity in naïve chronic hepatitis B patients.
    Lee JS; Park ET; Kang SS; Gu ES; Kim JS; Jang DS; Lee KS; Lee JS; Park NH; Bae CH; Baik SK; Yu BJ; Lee SH; Lee EJ; Park SI; Bae M; Shin JW; Choi JH; Gu C; Moon SK; Chun GJ; Kim JH; Kim HS; Choi SK
    Intervirology; 2010; 53(2):83-6. PubMed ID: 19955812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B.
    Lim SG; Krastev Z; Ng TM; Mechkov G; Kotzev IA; Chan S; Mondou E; Snow A; Sorbel J; Rousseau F
    Antimicrob Agents Chemother; 2006 May; 50(5):1642-8. PubMed ID: 16641430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of entecavir switching therapy in chronic hepatitis B patients with clevudine-induced myopathy].
    Lee JW; Lee YJ; Lee JJ; Kim JH; Jung YK; Kwon OS; Choi DJ; Kim YS; Kim JH
    Korean J Gastroenterol; 2013 Jan; 61(1):30-6. PubMed ID: 23354347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.